Varenicline — Chantix — is the most effective smoking cessation medication available. The mechanism is partial agonism at the α4β2 nicotinic acetylcholine receptor, providing approximately 30-40 percent of nicotine's full receptor activation. The dual effect that emerges from this partial agonism is what makes varenicline work: it reduces craving and withdrawal (the partial activation), and it blocks the reinforcement of smoking (the receptor occupancy that prevents inhaled nicotine from producing its full effect).
- Class
- Nicotinic acetylcholine receptor partial agonist (α4β2 subtype)
- Mechanism
- Partial agonist at α4β2 nicotinic ACh receptor: provides partial nicotinic stimulation (reduces craving and withdrawal) while blocking nicotine's full agonist effect (reduces reward from smoking)
- Typical dose
- 0.5 mg daily x3 days, 0.5 mg BID x4 days, then 1 mg BID for 12 weeks (or longer)
- Half-life
- ~24 hours
- FDA indications
- Smoking cessation in adults
- Key adverse effects
- Nausea (very common — take with food, water), insomnia, vivid dreams, headache, constipation. Earlier black-box for neuropsychiatric events (suicidality, depression) revoked in 2016 after large trial showed no significant difference vs placebo.
Most effective smoking cessation medication. Start 1-2 weeks before quit date (or use flexible quit approach). Combine with counseling. Discuss past neuropsychiatric concerns with patients but note current evidence does not support the prior black-box.
Head-to-head trial data are clear: varenicline outperforms NRT, bupropion, and placebo for quit rates. Combination with NRT may further improve outcomes. For the patient ready to quit smoking, varenicline is the most likely-to-work single intervention.
Varenicline aids smoking cessation through partial agonism at the nicotinic receptor — reducing craving while blunting the reward of smoking.
Mechanism note: Varenicline is the most effective single smoking-cessation pharmacotherapy — its partial agonism both eases withdrawal and blunts the reward of smoking; nausea and vivid dreams are the main tolerability issues.
Dosing starts before the quit date. Start 0.5 mg daily for 3 days, then 0.5 mg BID for 4 days, then 1 mg BID for the duration. Set a quit date 1-2 weeks after starting the medication so the receptor occupancy is established before the cessation attempt. Continue for 12 weeks at minimum; longer courses (24 weeks total) improve outcomes for some patients.
- Cost
- Generic ~$80-200/month. Brand Chantix discontinued/limited.
- Generic status
- Generic since 2020.
- Formulary typical
- Generic Tier 2. PA sometimes required.
- Access friction
- Some plans require failed NRT first. Counseling/quit-line referral often required for PA.
Prescriber tip: Document counseling/quit-line engagement for PA. Many state quit-lines offer free counseling that satisfies the requirement.
Nausea is the most common side effect — often dose-limiting early. Taking with food and water helps. Vivid dreams and insomnia occur. The titration is designed to mitigate side effects; rushing it increases discontinuation.
The black-box history matters. Initial FDA labeling included a black-box warning for neuropsychiatric events (suicidality, depression, agitation, behavioral changes) based on post-marketing reports. The EAGLES trial — large, randomized, included patients with psychiatric history — was conducted specifically to test this signal and found no significant excess of neuropsychiatric events compared to placebo or NRT. The FDA revoked the black box in 2016. Counsel honestly: monitor mood as with any new medication, but the evidence does not support meaningful excess risk.
For smoking cessation, varenicline is what works. Untreated smoking carries enormous mortality — don't let outdated concerns prevent appropriate prescribing.